ArticleCureus2025
Safe Treatment of an Extensive-Stage Small-Cell Lung Cancer With Tarlatamab in an Orthotopic Heart Transplantation Patient: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: Safety and efficacy of tarlatamab for SCLC in a liver transplant recipient.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graft rejection is the major challenge that solid organ transplant recipients face. As a consequence, lung cancer patients of this population have been consistently excluded from clinical trials involving the use of immunotherapy agents due to the increased risk of graft rejection. Tarlatamab is a novel bi-specific T-cell recruiter monoclonal antibody targeting delta-like ligand 3 (DLL3) on cancer cells and CD3 on T-cells; hence, it is theoretically much safer than other checkpoint inhibitor immunotherapy agents that boost T-cells non-specifically. Tarlatamab received Food and Drug Administration (FDA) approval in 2024 for the treatment of adults with extensive-stage small-cell lung cancer (ES-SCLC) that has progressed on or after platinum-based chemotherapy. Here, we report safe treatment of an extensive-stage small-cell lung cancer patient with an orthotopic heart transplant with tarlatamab. The patient received four doses between April and June 2025 without evidence of graft rejection or dysfunction. As of August 2025, the patient continues treatment without any adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.